308 related articles for article (PubMed ID: 15556931)
1. Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila.
Auluck PK; Meulener MC; Bonini NM
J Biol Chem; 2005 Jan; 280(4):2873-8. PubMed ID: 15556931
[TBL] [Abstract][Full Text] [Related]
2. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
Auluck PK; Chan HY; Trojanowski JQ; Lee VM; Bonini NM
Science; 2002 Feb; 295(5556):865-8. PubMed ID: 11823645
[TBL] [Abstract][Full Text] [Related]
3. Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro.
McLean PJ; Klucken J; Shin Y; Hyman BT
Biochem Biophys Res Commun; 2004 Aug; 321(3):665-9. PubMed ID: 15358157
[TBL] [Abstract][Full Text] [Related]
4. A Drosophila model of Parkinson's disease.
Feany MB; Bender WW
Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
[TBL] [Abstract][Full Text] [Related]
5. Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease.
Flower TR; Chesnokova LS; Froelich CA; Dixon C; Witt SN
J Mol Biol; 2005 Sep; 351(5):1081-100. PubMed ID: 16051265
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
7. Could a loss of alpha-synuclein function put dopaminergic neurons at risk?
Perez RG; Hastings TG
J Neurochem; 2004 Jun; 89(6):1318-24. PubMed ID: 15189334
[TBL] [Abstract][Full Text] [Related]
8. Proteomic approach to studying Parkinson's disease.
Zhang J; Goodlett DR
Mol Neurobiol; 2004 Jun; 29(3):271-88. PubMed ID: 15181239
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
10. Neuropathology in mice expressing human alpha-synuclein.
van der Putten H; Wiederhold KH; Probst A; Barbieri S; Mistl C; Danner S; Kauffmann S; Hofele K; Spooren WP; Ruegg MA; Lin S; Caroni P; Sommer B; Tolnay M; Bilbe G
J Neurosci; 2000 Aug; 20(16):6021-9. PubMed ID: 10934251
[TBL] [Abstract][Full Text] [Related]
11. [The mechanism of Lewy body formation in Parkinson's disease].
Wakabayashi K; Takahashi H
Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
[TBL] [Abstract][Full Text] [Related]
12. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT
J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226
[TBL] [Abstract][Full Text] [Related]
13. Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.
Junn E; Ronchetti RD; Quezado MM; Kim SY; Mouradian MM
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2047-52. PubMed ID: 12576551
[TBL] [Abstract][Full Text] [Related]
14. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
15. Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders.
Norris EH; Giasson BI
Antioxid Redox Signal; 2005; 7(5-6):672-84. PubMed ID: 15890012
[TBL] [Abstract][Full Text] [Related]
16. The cellular pathology of Parkinson's disease.
Takahashi H; Wakabayashi K
Neuropathology; 2001 Dec; 21(4):315-22. PubMed ID: 11837539
[TBL] [Abstract][Full Text] [Related]
17. Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice.
Shen HY; He JC; Wang Y; Huang QY; Chen JF
J Biol Chem; 2005 Dec; 280(48):39962-9. PubMed ID: 16210323
[TBL] [Abstract][Full Text] [Related]
18. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function.
Tofaris GK; Razzaq A; Ghetti B; Lilley KS; Spillantini MG
J Biol Chem; 2003 Nov; 278(45):44405-11. PubMed ID: 12923179
[TBL] [Abstract][Full Text] [Related]
20. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry.
Braak H; Sandmann-Keil D; Gai W; Braak E
Neurosci Lett; 1999 Apr; 265(1):67-9. PubMed ID: 10327208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
